

Glattpark, Switzerland, March 16th, 2023

## Pharma Manufacturing Forum


### - Emissions Reduction Memorandum -

To secure our health, own future as well as that of future generations, the climate change and nature loss threat need to be tackled. We, as Global Heads of Manufacturing and Supply Chain Operations, understand we can only achieve our own targets for sustainability by working together with you, our partners. Therefore, we are sharing this joint Memorandum to provide you with our perspective on how you can best contribute to help deliver environmental benefits across global supply chains.

Your contribution ideally includes the following measures and actions:

- Assess and disclose scope 1 and 2 emissions<sup>1</sup>
- Set and gain verification of science-based targets aligned with the 1.5 degree pathway
- Cascade standards and expectations related to upstream suppliers for disclosure<sup>2</sup>
- Switch to renewable power in own operations to the extent possible

This Memorandum is not replacing any existing program or commitment, but it aims at disclosing our intent to scale collective action for positive change. It remains compliant with all applicable anti-trust and competition laws to the respect of which we are fully committed.




Stephen Muldoon  
AbbVie



Esteban Santos  
Amgen



Pam Cheng  
AstraZeneca



Holger Weintritt  
Bayer Pharmaceuticals



Karin Shanahan  
Bristol Myers Squibb




Torsten Mau  
Boehringer Ingelheim




Edgardo Hernandez  
Eli Lilly




Stacey Ma  
Gilead Sciences



Regis J. Simard  
GSK



Sanat Chattopadhyay  
Merck & Co. Inc., USA, known as MSD outside of US and Canada



Teresa Rodo  
Merck, known as Merck KGaA, Darmstadt, Germany in US and Canada



Henrik Wulff  
Novo Nordisk



Mike McDermott  
Pfizer



Susanne Hundsbaek-Pedersen  
Roche



Brendan O'Callaghan  
Sanofi



Thomas Wozniowski  
Takeda



Kirsten Lund-Jurgensen  
UCB



Oladapo Ajayi  
Janssen



Steffen Lang  
Novartis

<sup>1</sup> For 1 and 2: bilaterally to your contractual partners or preferably in public, as permissible